Bruker Debuts Label-Free iNTApharma; Chemspeed-SciY Unveil SelfDriving Lab Platform
Bruker launched iNTApharma, a label-free nanoparticle characterization platform offering high-throughput sizing and concentration analysis for mRNA drug and gene therapy development and quality control workflows. Chemspeed and SciY introduced a SelfDriving Laboratory Platform integrating automated synthesis, real-time analytics and AI orchestration to accelerate R&D processes.
1. Bruker Introduces iNTApharma Platform
Bruker unveiled iNTApharma, a label-free nanoparticle characterization system designed to measure particle size, distribution and concentration without labels or standards. The platform targets mRNA drug and gene therapy developers, offering streamlined quality control workflows and rapid data output.
2. Potential Market Impact for Bruker
By addressing a critical need in mRNA and gene therapy QC, iNTApharma positions Bruker to capture recurring instrument sales and service contracts within a high-growth biopharma segment. Adoption by leading developers could drive incremental revenue and strengthen Bruker’s footprint in cell and gene therapy markets.
3. Chemspeed and SciY Launch SelfDriving Lab
Chemspeed and SciY introduced a SelfDriving Laboratory Platform that combines automated synthesis hardware, real-time analytical modules and AI orchestration software. The integrated system aims to optimize experiment design, reduce manual intervention and accelerate discovery timelines in chemical and materials research.